– Terapia de Ressincronização Cardíaca

A insuficiência cardíaca é uma significante causa de morbidade e mortalidade em todo o mundo, com prevalência de 2,4% dos adultos 1 (A). Embora a sobrevivência após o diagnóstico de insuficiência cardíaca tenha melhorado nas duas últimas décadas, as taxas de morte e hospitalização por insuficiência cardíaca permanecem altas e aproximadamente 50% dos pacientes morrem dentro de 5 anos do diagnóstico 1 (A). Adicionalmente, a despeito do tratamento medicamentoso otimizado, muitos pacientes com insuficiência cardíaca permanecem sintomáticos e com redução da qualidade de vida 2 (D)

– Cardiodesfibrilador Implantável – Infecção em DCEI – Papel dos Fármacos Antiarrítmicos – Direção Veicular em Portadores de DCEI

Desde o primeiro implante, em 1980, até os dias atuais, ocorreram importantes avanços no cardiodesfibrilador implantável (CDI), tanto no tamanho como nas funções e programações. Atualmente esses dispositivos dispõem de terapia antitaquicardia (ATP), cardioversão com baixa energia, desfibrilação com alta energia e função antibradicardia de backup. Diversos estudos de grande porte demonstraram que o CDI trata efetivamente os eventos de taquicardia ventricular e fibrilação ventricular, reduzindo a mortalidade quando comparado com fármacos antiarrítmicos isoladamente.[...

– Implante de Marcapasso nas Bradicardias e em Outras Situações Especiais – Estratificação de Risco de Morte Súbita na Cardiomiopatia Chagásica

A frequência cardíaca normal varia de 60 bpm a 100 bpm. Ritmos com frequência cardíaca < 60 bpm são definidos como bradicardia, que pode ser assintomática ou sintomática. As bradicardias sintomáticas têm características clínicas comuns, marcadas, sobretudo, pela síndrome do baixo fluxo cerebral e/ou sistêmico, cujos sintomas mais comuns são tontura, pré-síncope, síncope, fadiga, dispneia de esforço e bradipsiquismo, sendo comumente ocasionadas por doença do nó sinusal e bloqueio atrioventricular. As assintomáticas, geralmente, são de causas fisiológicas, representadas por bradicardia sinusal e ritmos de escape da junção atrioventricular

Soybean Trihelix Transcription Factors GmGT-2A and GmGT-2B Improve Plant Tolerance to Abiotic Stresses in Transgenic Arabidopsis

BACKGROUND:Trihelix transcription factors play important roles in light-regulated responses and other developmental processes. However, their functions in abiotic stress response are largely unclear. In this study, we identified two trihelix transcription factor genes GmGT-2A and GmGT-2B from soybean and further characterized their roles in abiotic stress tolerance. FINDINGS:Both genes can be induced by various abiotic stresses, and the encoded proteins were localized in nuclear region. In yeast assay, GmGT-2B but not GmGT-2A exhibits ability of transcriptional activation and dimerization. The N-terminal peptide of 153 residues in GmGT-2B was the minimal activation domain and the middle region between the two trihelices mediated the dimerization of the GmGT-2B. Transactivation activity of the GmGT-2B was also confirmed in plant cells. DNA binding analysis using yeast one-hybrid assay revealed that GmGT-2A could bind to GT-1bx, GT-2bx, mGT-2bx-2 and D1 whereas GmGT-2B could bind to the latter three elements. Overexpression of the GmGT-2A and GmGT-2B improved plant tolerance to salt, freezing and drought stress in transgenic Arabidopsis plants. Moreover, GmGT-2B-transgenic plants had more green seedlings compared to Col-0 under ABA treatment. Many stress-responsive genes were altered in GmGT-2A- and GmGT-2B-transgenic plants. CONCLUSION:These results indicate that GmGT-2A and GmGT-2B confer stress tolerance through regulation of a common set of genes and specific sets of genes. GmGT-2B also affects ABA sensitivity

4. Section of Preventive Medicine

have been associated with outbreaks and multidrug resistance. We performed a retrospective thirteen-year surveillance study (1993 of the available isolates from 332 cases of tuberculosis tested of an immigrant patient from Senegal with pulmonary tuberculosis. The strain was not drug resistant and besides six close contact persons that were infected no secondary cases of this strain were low and there is no evidence of transmission or higher virulence. Molecular epidemiology studies have revealed a genotype of M. tuberculosis strains that seem to possess selective advantages compared with other strains, have increased virulence and are sometimes associated with multidrug resistance [1,2]. This it is widespread around the world. The fact that this family of strains is widespread and, in some situations, associated with multidrug resistance has led to concern that these strains may be spreading the study of trends over time is of great interest. However, report